Numerous UT MD Anderson Meet the Experts are scheduled throughout ASCO. Note: All times are listed in Central Time.
Saturday, May 30
9:45¨C10:15 a.m.
Advances in lymphoma and multiple myeloma
Andrew Harkins, M.D.
Fellow, Cancer Medicine
Krina Patel, M.D.
Associate Professor, Lymphoma and Myeloma
10:30¨C11 a.m.
Preventive ethics in oncology
Associate Vice President, Clinical Ethics and Goal?Concordant Care
Associate Professor, Critical Care Medicine
11¨C11:30 a.m.
Partnering with health systems to eliminate cancer
Director, Leukemia for Cancer Network
11:30 a.m.¨C12 p.m.
Clinical trials at UT MD Anderson
Division Head, Cancer Medicine
Vice President, Clinical Research
Professor, Breast Medical Oncology
12:15¨C12:45 p.m.
Post-surgery management of brain metastases (Abstract LBA2000)
Professor, Melanoma Medical Oncology
Deputy Chair and Professor, Neurosurgery
1¨C1:30 p.m.
Spotlight on sarcoma, Part 1
Professor, Sarcoma Medical Oncology
Assistant Professor, Sarcoma Medical Oncology
1:30¨C2 p.m.
Psychedelic-assisted therapies in oncology
Assistant Professor, Head and Neck Surgery
Assistant Professor, Genomic Medicine
3¨C3:30 p.m.
New horizons in kidney cancer treatment
Assistant Professor, Genitourinary Medical Oncology
Professor, Genitourinary Medical Oncology
Associate Professor, Genitourinary Medical Oncology
3¨C5 p.m.
UT MD Anderson President
Peter WT Pisters, M.D.
President
3:30¨C4 p.m.
KRAS: Not just one target, Part 1
Professor, Gastrointestinal Medical Oncology
4:15¨C4:45 p.m.
Practice-changing advances for non-small cell lung cancer
Chair and Professor, Thoracic/Head and Neck Medical Oncology
Associate Professor, Thoracic/Head and Neck Medical Oncology
Sunday, May 31
9¨C9:30 a.m.
UT MD Anderson research enterprise
Chief Scientific Officer
Emily Roarty, Ph.D.
Vice President, Research Strategy and Impact
9:30¨C10 a.m.
Accelerating discoveries with industry partnerships
Emily Barnhill?
Vice President, Strategic Industry Ventures
Aaron Spike
Director, Strategic Industry Ventures
9:30¨C10 a.m.
Advances in targeted therapy in leukemia
Ad Interim Chair, Leukemia
Associate Professor, Leukemia
10:15¨C10:45 a.m.
Integrative strategies for young-onset colorectal cancer, Part 1
Professor, Colon and Rectal Surgery
Medical Director, Young-onset Colorectal Cancer Program
Professor, Colon & Rectal Surgery
10:30¨C11 a.m.
The expansion of antibody drug conjugates
Assistant Professor, Investigational Cancer Therapeutics
11¨C11:30 a.m.
Advancing immunotherapy through novel combinations, Part 1
Vice President, Head of Clinical Development, Therapeutics Discovery Division
Professor, Department of Investigational Cancer Therapeutics
11:30 a.m.¨C12 p.m.
Training at UT MD Anderson: Hematology/oncology fellowship
Program Director, Hematology/Oncology Fellowship Program
Associate Professor, Thoracic/Head and Neck Medical Oncology
Hannah Goulart, M.D.
Fellow, Cancer Medicine
Associate Program Director, Hematology/Oncology Fellowship Program
12¨C12:30 p.m.
The gold standard in breast cancer treatment, Part 1
Associate Professor, Breast Medical Oncology
Deputy Chair and Associate Professor, Breast Medical Oncology
12:30¨C1 p.m.
Integrative strategies for young-onset colorectal cancer, Part 2
Associate Professor, Gastrointestinal Medical Oncology
1:45¨C2:15 p.m.
The gold standard in breast cancer treatment, Part 2
Chair and Professor, Breast Medical Oncology
4¨C4:30 p.m.
The interception of cancer
Professor, Clinical Cancer Prevention
Professor, Gastrointestinal Medical Oncology
Monday, June 1
10¨C10:30 a.m.
Neoadjuvant therapy: Maximize cure and minimize harm
Professor, Radiation Oncology
10:45¨C11:15 a.m.
Liquid biopsies as decision tools in colorectal cancer
Professor, Gastrointestinal (GI) Medical Oncology
11:15¨C11:45 a.m.
Advancing immunotherapy through novel combinations, Part 2
Professor, Investigational Cancer Therapeutics
11:30 a.m.¨C12 p.m.
Spotlight on sarcoma, Part 2
Assistant Professor, Radiation Oncology
11:30 a.m.¨C12 p.m. (David Hong)
12¨C12:30 p.m. (Ferdinandos Skoulidis)
KRAS: Not just one target, Part 2
Deputy Chair, Investigational Cancer Therapeutics
Associate Professor, Thoracic/Head and Neck Medical Oncology
2¨C2:30 p.m.
Multi-cancer early detection tests: Are we ready?
Chair Ad Interim and Professor, Health Services Research
Vice President, Cancer Prevention and Population Sciences